

Pfenex Inc. to Present at Oppenheimer's 28th Annual Healthcare Conference

SAN DIEGO, March 13, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE AMERICAN: PFNX), announced today that the company will present at Oppenheimer's 28th Annual Healthcare Conference in New York City.

President and Chief Executive Officer, Eef Schimmelpennink, is scheduled to present on Tuesday, March 20, 2018 from 4:30 PM - 5:00 PM ET in the Track 2 room.

Interested parties can access the live audio webcast for this presentation from the Investors Section of Pfenex's website at www.pfenex.com. The webcast replay will be available after the conclusion of the live presentation for approximately 60 days.

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (<http://www.pfenex.com/>), our investor relations website (<http://pfenex.investorroom.com/>), press releases, SEC filings, public conference calls, corporate Twitter account (<https://twitter.com/pfenex>), Facebook page (<https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/>), and LinkedIn page (<https://www.linkedin.com/company/pfenex-inc>) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

About Pfenex Inc.

Pfenex Inc. is a clinical-stage biotechnology company developing complex therapeutic proteins. Using the patented Pfenex Expression Technology[®] platform, the Company has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. The Company's lead product candidates are PF708, a therapeutic equivalent candidate to Forteo[®] (teriparatide) for the treatment of osteoporosis, and its novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the US government. In addition, Pfenex is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals. Furthermore, the Company's pipeline includes biosimilar candidates to Lucentis[®] and Neulasta[®].

SOURCE Pfenex Inc.

For further information: Susan A. Knudson, Chief Financial Officer, (858) 352-4324, sknudson@pfenex.com
